Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 25, 2021 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Names Former Celgene Chairman and CEO, Mark Alles, to Chair Its Board of Directors

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
May 17, 2021 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer

SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
May 05, 2021 16:05 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational Updates

FDA Type B Meeting Feedback Supports Discussion of Topline BICR Results for Repotrectinib in TKI-Naïve ROS1+ NSCLC Patients After 6 Months or Greater Follow-up; FDA Meeting Anticipated in 1Q 2022 ...
April 26, 2021 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Host First Quarter 2021 Conference Call

SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
April 12, 2021 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor

Investigational New Drug Application Cleared Study Initiated in Australia, with U.S. Site Activations Now Planned SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc....
April 09, 2021 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates

SAN DIEGO, April 09, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
April 05, 2021 16:01 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046

Preliminary Clinical Activity Shown, With Tumor Regression in 4 of 5 TKI-Naïve Patients Including 2 Confirmed Partial ResponsesPreliminary Clinical Activity Shown, With Tumor Regression in 3 of 9...
March 31, 2021 16:05 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Announces Board Changes

Barbara Bodem Joins Board, Appointed Chair of Audit Committee Garry Nicholson Appointed as Interim Board Chair SAN DIEGO, March 31, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc....
March 10, 2021 18:08 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual Meeting

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
March 04, 2021 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...